Regeneron Pharmaceuticals, Inc. (REGN) Stock Chart
NasdaqGSView the Regeneron Pharmaceuticals, Inc. stock chart with market data, key statistics, volume, financial metrics, latest news, and exportable historical data.
Market data is for research and educational use only, not investment advice. Quotes may be delayed depending on the source and exchange; verify important prices with your broker or data provider.
Read the REGN trend first
Use the range controls to compare short-term moves with the longer-term Regeneron Pharmaceuticals, Inc. stock chart. A move that looks large on 1D can look routine on a 1Y or 5Y chart.
Check price with volume
Volume helps show whether a move happened with broad participation or thin trading. Compare recent bars with the average volume and news context before drawing conclusions.
Verify before acting
This page is built for research and education. Quotes, analyst fields, and news can be delayed or revised, so verify important prices with your broker or primary data provider.
Key Statistics
Financial Metrics
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Related Charts
Data Definitions
Previous close
The most recent prior regular-session close reported by the market data source.
Day range
The source-reported high and low for the current or most recent trading session.
Volume
The number of shares, units, contracts, or asset quantity reported as traded during the period.
Moving averages
The 50-day and 200-day averages smooth recent prices to give quick trend context.
Market cap
A company or fund size estimate based on price and shares outstanding when source data is available.
P/E ratio
Price divided by earnings per share. It is most useful when compared with peers and growth expectations.